Selected research
Industry Research
Monoclonal Antibodies for Plaque Psoriasis Industry Research Report 2026
Market perspective
The global Monoclonal Antibodies for Plaque Psoriasis market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Monoclonal Antibodies for Plaque Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Monoclonal Antibodies for Plaque Psoriasis is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Monoclonal Antibodies for Plaque Psoriasis is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Monoclonal Antibodies for Plaque Psoriasis include AbbVie, Inc., Almirall SA, Bausch Health Cos., Inc, Biocon Ltd., Janssen Biotech, Inc., Sun Pharmaceutical Industries Ltd., UCB, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd and Eli Lilly & Co., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Monoclonal Antibodies for Plaque Psoriasis market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Monoclonal Antibodies for Plaque Psoriasis Market by Company
AbbVie, Inc.
Almirall SA
Bausch Health Cos., Inc
Biocon Ltd.
Janssen Biotech, Inc.
Sun Pharmaceutical Industries Ltd.
UCB, Inc.
Jiangsu Hengrui Pharmaceuticals Co., Ltd
Eli Lilly & Co.
Novartis AG
Chongqing Genrix Biopharmaceutical Co., Ltd
Monoclonal Antibodies for Plaque Psoriasis Segment by Type
5-100 mg/mL
100-200 mg/mL
Monoclonal Antibodies for Plaque Psoriasis Segment by Application
Hospital
Clinic
Others
Monoclonal Antibodies for Plaque Psoriasis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Monoclonal Antibodies for Plaque Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Monoclonal Antibodies for Plaque Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Monoclonal Antibodies for Plaque Psoriasis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Monoclonal Antibodies for Plaque Psoriasis manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Monoclonal Antibodies for Plaque Psoriasis by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Monoclonal Antibodies for Plaque Psoriasis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 5-100 mg/mL
- 100-200 mg/mL
Applications
- Hospital
- Clinic
- Others
Companies covered
- AbbVie, Inc.
- Almirall SA
- Bausch Health Cos., Inc
- Biocon Ltd.
- Janssen Biotech, Inc.
- Sun Pharmaceutical Industries Ltd.
- UCB, Inc.
- Jiangsu Hengrui Pharmaceuticals Co., Ltd
- Eli Lilly & Co.
- Novartis AG
- Chongqing Genrix Biopharmaceutical Co., Ltd
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Monoclonal Antibodies for Plaque Psoriasis Market Size (2021-2032)
- 2.2.2 Global Monoclonal Antibodies for Plaque Psoriasis Sales (2021-2032)
- 2.2.3 Global Monoclonal Antibodies for Plaque Psoriasis Market Average Price (2021-2032)
- 2.3 Monoclonal Antibodies for Plaque Psoriasis by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 5-100 mg/mL
- 2.3.3 100-200 mg/mL
- 2.4 Monoclonal Antibodies for Plaque Psoriasis by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Monoclonal Antibodies for Plaque Psoriasis Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Monoclonal Antibodies for Plaque Psoriasis Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Monoclonal Antibodies for Plaque Psoriasis Revenue of Manufacturers (2021-2026)
- 3.4 Global Monoclonal Antibodies for Plaque Psoriasis Average Price by Manufacturers (2021-2026)
- 3.5 Global Monoclonal Antibodies for Plaque Psoriasis Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Monoclonal Antibodies for Plaque Psoriasis, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Monoclonal Antibodies for Plaque Psoriasis, Product Type & Application
- 3.8 Global Manufacturers of Monoclonal Antibodies for Plaque Psoriasis, Established Date
- 3.9 Global Monoclonal Antibodies for Plaque Psoriasis Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 AbbVie, Inc.
- 4.1.1 AbbVie, Inc. Company Information
- 4.1.2 AbbVie, Inc. Business Overview
- 4.1.3 AbbVie, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 AbbVie, Inc. Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
- 4.1.5 AbbVie, Inc. Recent Developments
- 4.2 Almirall SA
- 4.2.1 Almirall SA Company Information
- 4.2.2 Almirall SA Business Overview
- 4.2.3 Almirall SA Monoclonal Antibodies for Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Almirall SA Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
- 4.2.5 Almirall SA Recent Developments
- 4.3 Bausch Health Cos., Inc
- 4.3.1 Bausch Health Cos., Inc Company Information
- 4.3.2 Bausch Health Cos., Inc Business Overview
- 4.3.3 Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
- 4.3.5 Bausch Health Cos., Inc Recent Developments
- 4.4 Biocon Ltd.
- 4.4.1 Biocon Ltd. Company Information
- 4.4.2 Biocon Ltd. Business Overview
- 4.4.3 Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
- 4.4.5 Biocon Ltd. Recent Developments
- 4.5 Janssen Biotech, Inc.
- 4.5.1 Janssen Biotech, Inc. Company Information
- 4.5.2 Janssen Biotech, Inc. Business Overview
- 4.5.3 Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
- 4.5.5 Janssen Biotech, Inc. Recent Developments
- 4.6 Sun Pharmaceutical Industries Ltd.
- 4.6.1 Sun Pharmaceutical Industries Ltd. Company Information
- 4.6.2 Sun Pharmaceutical Industries Ltd. Business Overview
- 4.6.3 Sun Pharmaceutical Industries Ltd. Monoclonal Antibodies for Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sun Pharmaceutical Industries Ltd. Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
- 4.6.5 Sun Pharmaceutical Industries Ltd. Recent Developments
- 4.7 UCB, Inc.
- 4.7.1 UCB, Inc. Company Information
- 4.7.2 UCB, Inc. Business Overview
- 4.7.3 UCB, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 UCB, Inc. Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
- 4.7.5 UCB, Inc. Recent Developments
- 4.8 Jiangsu Hengrui Pharmaceuticals Co., Ltd
- 4.8.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd Company Information
- 4.8.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd Business Overview
- 4.8.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
- 4.8.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd Recent Developments
- 4.9 Eli Lilly & Co.
- 4.9.1 Eli Lilly & Co. Company Information
- 4.9.2 Eli Lilly & Co. Business Overview
- 4.9.3 Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
- 4.9.5 Eli Lilly & Co. Recent Developments
- 4.10 Novartis AG
- 4.10.1 Novartis AG Company Information
- 4.10.2 Novartis AG Business Overview
- 4.10.3 Novartis AG Monoclonal Antibodies for Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Novartis AG Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
- 4.10.5 Novartis AG Recent Developments
- 4.11 Chongqing Genrix Biopharmaceutical Co., Ltd
- 4.11.1 Chongqing Genrix Biopharmaceutical Co., Ltd Company Information
- 4.11.2 Chongqing Genrix Biopharmaceutical Co., Ltd Business Overview
- 4.11.3 Chongqing Genrix Biopharmaceutical Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Chongqing Genrix Biopharmaceutical Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
- 4.11.5 Chongqing Genrix Biopharmaceutical Co., Ltd Recent Developments
5 Global Monoclonal Antibodies for Plaque Psoriasis Market Scenario by Region
- 5.1 Global Monoclonal Antibodies for Plaque Psoriasis Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Region: 2021-2032
- 5.2.1 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Region: 2021-2026
- 5.2.2 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Region: 2027-2032
- 5.3 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Region: 2021-2032
- 5.3.1 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Region: 2021-2026
- 5.3.2 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Region: 2027-2032
- 5.4 North America Monoclonal Antibodies for Plaque Psoriasis Market Facts & Figures by Country
- 5.4.1 North America Monoclonal Antibodies for Plaque Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Monoclonal Antibodies for Plaque Psoriasis Sales by Country (2021-2032)
- 5.4.3 North America Monoclonal Antibodies for Plaque Psoriasis Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Monoclonal Antibodies for Plaque Psoriasis Market Facts & Figures by Country
- 5.5.1 Europe Monoclonal Antibodies for Plaque Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Monoclonal Antibodies for Plaque Psoriasis Sales by Country (2021-2032)
- 5.5.3 Europe Monoclonal Antibodies for Plaque Psoriasis Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Monoclonal Antibodies for Plaque Psoriasis Market Facts & Figures by Country
- 5.6.1 Asia Pacific Monoclonal Antibodies for Plaque Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Monoclonal Antibodies for Plaque Psoriasis Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Monoclonal Antibodies for Plaque Psoriasis Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Monoclonal Antibodies for Plaque Psoriasis Market Facts & Figures by Country
- 5.7.1 South America Monoclonal Antibodies for Plaque Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Monoclonal Antibodies for Plaque Psoriasis Sales by Country (2021-2032)
- 5.7.3 South America Monoclonal Antibodies for Plaque Psoriasis Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Type (2021-2032)
- 6.1.1 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Type (2021-2032)
- 6.2 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Type (2021-2032)
- 6.2.1 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Type (2021-2032)
- 6.3 Global Monoclonal Antibodies for Plaque Psoriasis Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Application (2021-2032)
- 7.1.1 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Application (2021-2032)
- 7.2 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Application (2021-2032)
- 7.2.1 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Application (2021-2032)
- 7.3 Global Monoclonal Antibodies for Plaque Psoriasis Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Monoclonal Antibodies for Plaque Psoriasis Value Chain Analysis
- 8.1.1 Monoclonal Antibodies for Plaque Psoriasis Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Monoclonal Antibodies for Plaque Psoriasis Production Mode & Process
- 8.2 Monoclonal Antibodies for Plaque Psoriasis Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Monoclonal Antibodies for Plaque Psoriasis Distributors
- 8.2.3 Monoclonal Antibodies for Plaque Psoriasis Customers
9 Global Monoclonal Antibodies for Plaque Psoriasis Analyzing Market Dynamics
- 9.1 Monoclonal Antibodies for Plaque Psoriasis Industry Trends
- 9.2 Monoclonal Antibodies for Plaque Psoriasis Industry Drivers
- 9.3 Monoclonal Antibodies for Plaque Psoriasis Industry Opportunities and Challenges
- 9.4 Monoclonal Antibodies for Plaque Psoriasis Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst